UBS Group Issues Positive Forecast for Solventum (NYSE:SOLV) Stock Price

Solventum (NYSE:SOLV) had its price target lifted by UBS Group from $77.00 to $79.00 in a research report sent to investors on Monday,Benzinga reports. UBS Group currently has a neutral rating on the stock.

Several other analysts also recently weighed in on the company. Wells Fargo & Company boosted their price objective on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. Piper Sandler lifted their target price on shares of Solventum from $94.00 to $98.00 and gave the stock an “overweight” rating in a research note on Friday. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a report on Thursday, October 30th. Morgan Stanley raised shares of Solventum from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. Finally, Wall Street Zen cut shares of Solventum from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 9th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $85.56.

Solventum Stock Performance

NYSE SOLV opened at $71.83 on Monday. The company has a 50-day simple moving average of $71.94 and a two-hundred day simple moving average of $72.51. Solventum has a 12-month low of $60.70 and a 12-month high of $85.92. The firm has a market cap of $12.46 billion, a price-to-earnings ratio of 8.28, a PEG ratio of 2.88 and a beta of 0.49. The company has a quick ratio of 1.14, a current ratio of 1.50 and a debt-to-equity ratio of 1.03.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.43 by $0.07. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The firm had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. During the same quarter in the previous year, the business earned $1.64 earnings per share. The company’s quarterly revenue was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, equities analysts forecast that Solventum will post 6.58 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Strengthening Families & Communities LLC increased its position in shares of Solventum by 376.8% during the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after buying an additional 260 shares during the period. Deseret Mutual Benefit Administrators boosted its position in Solventum by 78.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after acquiring an additional 163 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new position in shares of Solventum during the 2nd quarter worth approximately $28,000. Barrett & Company Inc. raised its position in shares of Solventum by 206.2% in the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock worth $30,000 after acquiring an additional 268 shares in the last quarter. Finally, IMG Wealth Management Inc. bought a new position in shares of Solventum in the 2nd quarter worth approximately $31,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.